Drug Discovery World

AUGUST 12, 2024

In this event, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, will present his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy.

Virus 130

Virus Therapies Clinical Trials Engineering 130

Drug Discovery World

AUGUST 7, 2024

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. It is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection.

Drug Trials 148

Drug Trials FDA Trials Immune Response 148

Drug Discovery World

DECEMBER 19, 2023

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). The patient was dosed without the need for a chemotherapy (required for gene modified stem cells) or immunosuppression (required for systemic virus-delivered gene therapy).

Engineering 285

Engineering Therapies Trials Medical Schools 285

Drug Discovery World

JUNE 6, 2023

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. The FDA’s decision is based on the data from the pivotal Phase III clinical trial RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease).

FDA Approval 130

FDA Approval Virus Vaccine FDA 130

Drug Discovery World

SEPTEMBER 9, 2022

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of advanced cancers.

Virus 130

Virus Research Immune Response Engineering 130

Drug Discovery World

DECEMBER 22, 2022

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. . The post AI identifies drug candidates for respiratory syncytial virus appeared first on Drug Discovery World (DDW).

Virus 130

Virus Clinical Trials Drugs Hospitals 130

Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus.

Vaccine 130

Vaccine Trials Animal Testing Virus 130

Drug Discovery World

FEBRUARY 8, 2023

Dengue is the fastest spreading mosquito-borne virus and was recognised by the World Health Organization (WHO) in 2019 as one of the top ten threats to global health. An estimated 3.9 The post UK approval for dengue virus vaccine candidate appeared first on Drug Discovery World (DDW).

Virus 130

Virus Vaccine Trials Production 130

Drug Discovery World

SEPTEMBER 15, 2023

Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. Rabies, RBI-4000 and the Phase I trial Rabies remains a public health threat in several geographical regions and is designated an NIAID Priority Pathogen.

Vaccine 130

Vaccine Trials Immune Response Virus 130

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus. Official comments .

Clinical Trials 130

Clinical Trials Trials Virus Vaccine 130

Drug Discovery World

SEPTEMBER 18, 2023

Next generation Covid-19 vaccines could have the potential to expand the breadth of coverage against existing and future variants of the virus, extend the duration of protection, and offer better protection in the prevention of illness and transmission over the current state of vaccine technologies.

Clinical Trials 130

Clinical Trials Vaccine Trials Government 130

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

AUGUST 23, 2022

A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France. . The post Bayer gets go-ahead for Huntington’s Disease gene therapy trial appeared first on Drug Discovery World (DDW).

Therapies 246

Therapies Disease Trials Clinical Trials 246

Drugs.com

AUGUST 1, 2024

1, 2024 -- A next-generation nasal vaccine for COVID-19 appears to do what injectable vaccines can’t -- actually stop the spread of the virus from person to person.Hamsters that received the nasal vaccine didn’t pass the virus on to. THURSDAY, Aug.

Vaccine 110

Vaccine Trials Virus 110

Drugs.com

SEPTEMBER 4, 2024

4, 2024 -- Current vaccines against mpox were designed to fight an older, rarer cousin of the virus, smallpox.Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a. WEDNESDAY, Sept.

Vaccine 98

Vaccine Trials Virus Research 98

Drug Discovery World

AUGUST 2, 2022

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. . Official comments .

Trials 130

Trials FDA Immune Response Clinical Trials 130

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drug Discovery World

JULY 12, 2024

Clinical trial news has caught our attention this week. Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease. Mission awarded $5.2m

Clinical Trials 130

Clinical Trials Virus Trials Vaccine 130

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccine 130

Vaccine Trials Clinical Trials Virus 130

Drug Discovery World

APRIL 14, 2023

Researchers from the University of Oxford have reported findings from a Phase II clinical trial investigating the efficacy of an investigational treatment against long Covid fatigue. Emerging data on long Covid suggests that the virus targets the mitochondrial, which are essential to normal energy generation and control of inflammation.

Treatment 130

Treatment Trials Clinical Trials Pharmaceutical Companies 130

ProRelix Research

SEPTEMBER 7, 2023

Autoimmune disorders comprise several diseases in which the immune system mistakenly attacks and destroys the body’s own healthy cells instead of destroying bacteria and viruses to keep the body healthy. […] The post Autoimmune disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.

Clinical Trials 105

Clinical Trials Trials Treatment Virus 105

Drug Discovery World

JULY 15, 2024

Clinical trial news has caught our attention this week. Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease.

Clinical Trials 130

Clinical Trials Virus Trials Disease 130

Drug Discovery World

APRIL 3, 2023

The findings indicate that a drug compound, R805/CX-011, may modulate an important cell receptor in the body’s immune system, GP130, that signals when antibodies should attack a virus or infection. The post Potentially ‘regenerative’ osteoarthritis drug moves to clinical trial appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Trials FDA Approval Drugs 130

Drug Discovery World

JULY 15, 2024

Clinical trial news has caught our attention this week. Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease.

Clinical Trials 130

Clinical Trials Virus Trials Disease 130

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccine 130

Vaccine Immune Response RNA Virus 130

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. For example, a site conducting only protocols involving mRNA may be able to leverage a generic SOP covering any mRNA protocol at that site.

Clinical Trials 52

Clinical Trials Engineering Trials Virus 52

The Pharma Data

APRIL 27, 2023

The positive opinion is supported by data from the pivotal AReSVi-006 ( A dult R espiratory S yncytial V irus) phase III vaccine efficacy trial. In the trial, the vaccine candidate showed 82.6% (96.95% CI, 57.9–94.1, Across multiple trials, the vaccine candidate was generally well tolerated with an acceptable safety profile.

Virus 40

Virus Vaccine Trials Clinical Trials 40

Drug Discovery World

AUGUST 24, 2022

The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment. As a community-based trial, participants will take the treatment or placebo in their own homes. The trial looks to include at least 500 participants in the UK. .

Research 246

Research Clinical Trials Virus Trials 246

Drug Discovery World

JUNE 28, 2024

This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as the launch of DDW’s latest In Focus report.

Clinical Trials 130

Clinical Trials Drugs Trials Virus 130

Drug Discovery World

JUNE 28, 2024

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and Europe.

Therapies 148

Therapies Disease Medical Schools Trials 148

Drug Discovery World

APRIL 15, 2024

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials. At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV.

Vaccine 130

Vaccine Clinical Trials Trials Virus 130

Drug Discovery World

MARCH 8, 2024

The top stories: Antibody therapy shows anti-tumour activity in advanced cancer In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer.

Clinical Trials 130

Clinical Trials FDA Virus Drugs 130

Drug Discovery World

DECEMBER 18, 2023

The researchers plan to conduct a first-in-human clinical trial in the next five years. For added safety, they used a virus that is unable to replicate to carry the potassium channel gene. They then injected either the virus carrying the EKC gene or a control virus into the affected brain area.

Therapies 265

Therapies Virus Regulations Clinical Trials 265

Drug Discovery World

AUGUST 9, 2024

Recombinant polyclonal drug trial for HBV gets FDA green light The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339.

FDA 130

FDA FDA Approval Engineering Drugs 130

Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Drug Discovery World

SEPTEMBER 22, 2023

As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have also reported on vaccine trials for a number of other conditions, including Nipah virus, rabies and lung cancer.

Vaccine 130

Vaccine Clinical Trials Virus Drugs 130

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52